GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » EV-to-Revenue

Yumanity Therapeutics (FRA:8IY) EV-to-Revenue : 2.51 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Yumanity Therapeutics's enterprise value is €11.53 Mil. Yumanity Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was €4.59 Mil. Therefore, Yumanity Therapeutics's EV-to-Revenue for today is 2.51.

The historical rank and industry rank for Yumanity Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:8IY's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.21
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Yumanity Therapeutics's stock price is €1.47. Yumanity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was €0.43. Therefore, Yumanity Therapeutics's PS Ratio for today is 3.45.


Yumanity Therapeutics EV-to-Revenue Historical Data

The historical data trend for Yumanity Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics EV-to-Revenue Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
EV-to-Revenue
- 17.88 2.82

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.29 2.82 1.75 1.78 1.82

Competitive Comparison of Yumanity Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Yumanity Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's EV-to-Revenue falls into.



Yumanity Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Yumanity Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=11.527/4.587
=2.51

Yumanity Therapeutics's current Enterprise Value is €11.53 Mil.
Yumanity Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yumanity Therapeutics  (FRA:8IY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Yumanity Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.47/0.426
=3.45

Yumanity Therapeutics's share price for today is €1.47.
Yumanity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.43.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yumanity Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines